Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 9/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578123 | 1.00 | KAT2B (0.51) | KAT2BRIPK1NPC1RAB9APOLB | |
| SCHEMBL577842 | 0.84 | HCRTR1 (0.41) | KAT2B | |
| SCHEMBL578231 | 0.84 | KAT2B (0.40) | KAT2B | |
| SCHEMBL577841 | 0.84 | HCRTR1 (0.41) | KAT2B | |
| SCHEMBL578230 | 0.84 | KAT2B (0.40) | KAT2B | |
| SCHEMBL578108 | 0.83 | NPC1 (0.52) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL578109 | 0.83 | NPC1 (0.52) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL578134 | 0.82 | KAT2B (0.40) | KAT2BRIPK1 | |
| SCHEMBL577720 | 0.82 | KAT2B (0.45) | KAT2B | |
| SCHEMBL578135 | 0.82 | KAT2B (0.40) | KAT2BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | COASY, LSS, INF2 | KAT2B 768/4885RIPK1 2179/4885NPC1 1671/4885 |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | CCNL2, ASH2L, AHR | KAT2B 948/4885RIPK1 954/4885NPC1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.